Nucleotide analogs as novel anti-hepatitis B virus agents

Current Opinion in Pharmacology

Volumn 5, Issue 5 SPEC.ISS., 2005, Pages 520-528

  Iyer, Radhakrishnan P ^a   Padmanabhan, Seetharamaiyer ^a   Zhang, Guangrong ^a   Morrey, John D ^b   Korba, Brent E ^c  

^a Spring Bank Pharmaceuticals Inc   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O OCTADECYL SN GLYCERO 3 PHOSPHOACYCLOVIR; 1,3 PROPANYL ESTER DERIVATIVE; 2',3 DIDEOXY 2',3 DIDEHYDRO 7 DEAAZAADENOSINE; 2',3 DIDEOXY 2',3 DIDEHYDRO 7 DEAAZAADENOSINE ALANINE BENZYL ESTER; 2',3 DIDEOXY 2',3 DIDEHYDRO 7 DEAAZAADENOSINE ALANINE METHYL ESTER; 2',3 DIDEOXY 2',3 DIDEHYDRO 7 DEAAZAADENOSINE DIMETHYLGLYCINE BENZYL ESTER; 2',3 DIDEOXY 2',3 DIDEHYDRO 7 DEAAZAADENOSINE PHENYLALANINE METHYL ESTER; 2,2 BIS(HYDROXYMETHYL)METHYLENECYCLOPROPANE DERIVATIVE; 9 (2 PHOSPHONOMETHOXYCYCLOPROPYL) 2,6 DIAMINOPURINE; 9 (2 PHOSPHONOMETHOXYCYCLOPROPYL)METHYLGUANINE; 9 (2 PHOSPHONOMETHOXYCYCLOPROPYL)METHYLGUANINE DIPIVOXIL; 9 (2 PHOSPHONOYLMETHOXYETHYL)ADENINE DERIVATIVE; ACICLOVIR; ACYL 2 THIOETHYL NUCLEOTIDE DERIVATIVE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ADENOSINE PHOSPHATE; ALAMIFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HYDROXYPHOSPHONOMETHOXYPROPYL 2,6 DIAMINOPURINE; LAMIVUDINE; N 1 PHOSPHONOMETHOXYETHYL DERIVATIVE; N 1 PHOSPHONOMETHOXYPROPYL DERIVATIVE; NUCLEOTIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; SALICYLIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DERIVATIZATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENCY; ELECTRICITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY TUBULE DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 24344464893     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.04.019     Document Type: Review

References (48)

1. D.E. Szymkowski Developing antisense oligonucleotides from the laboratory to clinical trials Drug Discov Today 1 1996 415-428
2. O.C. Uhlenbeck A small catalytic oligoribonucleotide Nature 328 1987 596-600
3. P.D. Zamore Ancient pathways programmed by small RNAs Science 296 2002 1265-1269
4. R.P. Iyer S. Kuchimanchi R.K. Pandey RNA interference: An exciting new approach for target validation, gene expression analysis and therapeutics Drugs Fut 28 2003 51-59
5. A.S. Lok Chronic hepatitis B N Engl J Med 346 2002 1682-1683
6. J.N. Zuckerman A.J. Zuckerman The epidemiology of hepatitis B Clin Liv Dis 3 1999 179-187
7. S.T. Goldstein M.J. Alter I.T. Williams L.A. Moyer F.N. Judson K. Mottram M. Fleenor P.L. Ryder H.S. Margolis et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: Implication for vaccination programs J Infect Dis 185 2002 713-719
8. K.W. Lin J.T. Kirchner Hepatitis B Am Fam Physician 69 2004 75-82
9. A.S. Lok B.J. McMahon Chronic hepatitis B Hepatology 34 2001 1225-1241
10. F. Nevens J. Main P. Honkoop D.L. Tyrrell J. Barber M.T. Sullivan J. Fevery R.A. De Man H.C. Thomas Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study Gastroenterology 113 1997 1258-1263
11. A.M. Abdelhamed C.M. Kelley T.G. Miller P.A. Furman H.C. Isom Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment J Virol 76 2002 8148-8160
12. M.I. Allen M. Deslauriers C.W. Andrews G.A. Tipples K.A. Walters D.L. Tyrrell N.C.L.D. Brown Identification and characterization of mutations in hepatitis B virus resistant to lamivudine Hepatology 27 1998 1670-1677
13. T. Shaw S. Bowden S. Locarnini Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? Gatroenterology 126 2004 343-350
14. T. Shaw S. Locarnini Entecavir for the treatment of chronic hepatitis B Expert Rev Anti Infect Ther 2 2004 853-871
15. K. Relucio M. Holodniy Role of deoxyribonucleoside kinases and deoxyribonucleotide pool alterations in nucleoside reverse transcriptase inhibitor induced mitochondrial toxicity Curr Med Chem - Anti-Infect Agents 2 2003 241-262
16. R. Fleischer D. Boxwell K.E. Sherman Nucleoside analogues and mitochondrial toxicity Clin Infect Dis 38 2004 e79-e80
17. C. Ying E. De Clercq J. Neyts Selective inhibitors of hepatitis B virus replication Curr Med Chem - Anti-Infect Agents 2 2003 227-240
18. J.C. Martin Nucleotide Analogues as Antiviral Agents 1989 ACS Washington
19. A.M. Rivkin Adefovir dipivoxil in the treatment of chronic hepatitis B Ann Pharmacother 38 2004 625-633
20. Holy A, De Clercq E, Votruba I: Phosphonylmethyl ethers of nucleosides and their acyclic analogues. In Nucleotide Analogues as Antiviral Agents. Washington: ACS; 1989:51-71.
21. P. Marcellin T.T. Chang S.G. Lim M.J. Tong W. Sievert M.L. Shiffman L. Jeffers Z. Goodman M.S. Wulfson S. Xiong et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808-816
22. E.S. Ho D.C. Lin D.B. Mendel T. Cihlar Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1 J Am Soc Nephrol 11 2000 383-393
23. G.J. Dore D.A. Cooper A.L. Pozniak E. DeJesus L. Zhong M.D. Miller B. Lu A.K. Cheng Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and experienced patients coinfected with HIV-1 and hepatitis B virus J Infect Dis 189 2004 1185-1192
24. C. Ying A. Holý D. Hocková Z. Havlas E. De Clercq J. Neyts Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities Antimicrob Agents Chemother 49 2005 1177-1180
25. J-R. Choi D-G. Cho K.Y. Roh J-T. Hwang S. Ahn H.S. Jang W-Y. Cho K.W. Kim Y-G. Cho J. Kim Y-Z. Kim A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent J Med Chem 47 2004 2864-2869
26. N. Kamiya A. Kubota Y. Iwase K. Sekiya M. Ubasawa S. Yuasa Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus Antimicrob Agents Chemother 46 2002 2872-2877
27. Z. Yan E.R. Kern E. Gullen Y-C. Cheng J.C. Drach J. Zemlicka Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: Synthesis and antiviral activity J Med Chem 48 2005 91-99
28. K.S. Gudmundsson Z. Wang S.M. Daluge L.C. Johnson R. Hazen L.D. Condreay C. McGuigan Phosphoramidate protides of carbocyclic 2,3′-dideoxy-2,3′-didehydro-7deazaadenosine with potent activity against HIV and HBV Nucleosides Nucleotides Nucleic Acids 23 2004 1929-1937
29. D. Cahard C. McGuigan J. Balzarini Aryloxy phosphoramidate triesters as pro-tides Mini Rev Med Chem 4 2004 371-381
30. G. Valette A. Pompon J-L. Girardet L. Cappellacci P. Franchetti M. Grifantini P. La Colla A.G. Loi C. Périgaud G. Gosselin J-L. Imbach Decomposition pathways and in vitro anti-HIV effects of isoddA pronucleotides - toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates J Med Chem 39 1996 1981-1990
31. D.P. Drontle C.R. Wagner Designing a pronucleotide strategem: Lessons from amino acid phosphoramidates of anticancer and antiviral pyrimidines Mini Rev Med Chem 4 2004 409-419
32. K.Y. Hostetler J.R. Beadle W.E. Hornbuckle C.A. Bellezza I.A. Tochkov P.J. Cote J.L. Gerin B.E. Korba B.C. Tennant Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic hepatitis virus infection Antimicrob Agents Chemother 44 2000 1964-1969
33. S. Peyrottes D. Egron I. Lefebre G. Gosselin J-L. Imbach C. Périgaud SATE pronucleotide approaches: An overview Mini Rev Med Chem 4 2004 395-408
34. C. Meier M.F.H. Ruppel D. Vukadinovic J. Balzarin 'Lock-in'-cycloSal-pronucleotides - a new generation of chemical trojan horses? Mini Rev Med Chem 4 2004 383-394
35. C. Anastasi P. Vlieghe O. Hantz O. Schorr C. Pannecouque M. Witvrouw E. De Clercq P. Clayette N. Dereuddre-Bosquet D. Dormont et al. Are 5′-O-carbamate-2′-3′-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? Bioorg Med Chem Lett 13 2003 2459-2463
36. 450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver J Am Chem Soc 126 2004 5154-5163
37. W. Sanger Principles of Nucleic Acid Structure 1983 Springer-Verlag
38. S.L. Schreiber Target-oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964-1969
39. W. Wood L. Huang J.A. Ellman Synthesis of a diverse library of mechanism-based cysteine protease inhibitors J Comb Chem 5 2003 869-880
40. Y. Xiao A. Roland Y. Jin R.P. Iyer A novel linker for the solid-phase synthesis of a library of 3′-thiophosphorylated dinucleotides Tetrahedron Lett 42 2001 3669-3672
41. Y. Jin X. Chen M-E. Cote A. Roland B. Korba S. Mounir R.P. Iyer Parallel solid-phase synthesis of nucleoside phosphoramidate libraries Bioorg Med Chem Lett 11 2001 2057-2060
42. Y. Jin A. Roland W. Zhou M. Fauchon J. Lyaku R.P. Iyer Synthesis and antiviral evaluation of nucleic acid-based (NAB™) libraries Bioorg Med Chem Lett 10 2000 1921-1925
43. W. Zhou S. Upendran A. Roland R.P. Iyer Nucleotide libraries as a source of biologically relevant chemical diversity: Solution-phase synthesis Bioorg Med Chem Lett 10 2000 1249-1252
44. R.P. Iyer Y. Jin A. Roland J.D. Morrey S. Mounir B. Korba Phosphorothioate di-and trinucleotides as a novel class of anti-hepatitis B virus agents Antimicrob Agents Chemother 48 2004 2199-2205
45. V. Nair Novel inhibitors of HIV integrase: The discovery of potential anti-HIV therapeutic agents Curr Pharm Des 9 2003 2553-2565
46. J.G. Julander R.J. Colonno R.W. Sidwell J.D. Morrey Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus Antiviral Res 59 2003 155-161
47. R.P. Iyer A. Roland Y. Jin S. Mounir B. Korba J.G. Julander J.D. Morrey Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model Antimicrob Agents Chemother 48 2004 2318-2320
48. J. Magden L. Kääriäinen T. Ahola Inhibitors of viral replication: Recent developments and prospects Appl Microbiol Biotechnol 66 2005 612-621